RESICARD: East Paris network for the management of heart failure: Absence of effect on mortality and rehospitalization in patients with severe heart failure admitted following severe decompensation  by Assyag, Patrick et al.
Archives of Cardiovascular Disease (2009) 102, 29—41
CLINICAL RESEARCH
RESICARD: East Paris network for the management of
heart failure: Absence of effect on mortality and
rehospitalization in patients with severe heart
failure admitted following severe decompensation
RESICARD : réseau Paris-Est pour la prise en charge des patients en insufﬁsance
cardiaque : absence d’effets sur la mortalité et les réhospitalisations chez les
patients en insufﬁsance cardiaque sévère inclus au décours d’une
décompensation sévère
Patrick Assyaga, Thomas Renaudb,
Alain Cohen-Solal c, Magali Viaudd, Henry Kryse,
Aleksandra Bundalod, Pierre-Louis Michel f,
Robert Boukobzag, Yann Bourgueil b, Ariel Cohend,∗
a 167, avenue Ledru-Rollin, 75011 Paris, France
b IRDES, 10, rue Vauvenargues, 75018 Paris, France
c Service de cardiologie, hôpital Lariboisière, 2, rue Ambroise-Paré, 75475 Paris cedex 10,
France
d Service de cardiologie, hôpital Saint-Antoine, AP—HP, université Pierre-et-Marie-Curie,
184, rue du Faubourg-Saint-Antoine, 75571 Paris cedex 12, France
e 73, boulevard Richard-Lenoir, 75011 Paris, France
f Service de cardiologie, hôpital Tenon, 4, rue de la Chine, 75970 Paris cedex 20, France
g Hôpital La-Roseraie, 120, avenue de la République, 93300 Aubervilliers, France
Received 6 October 2008; received in revised form 6 October 2008; accepted 7 October 2008
KEYWORDS
Heart failure;
Summary
Background.— Heart failure presents a major public health problem due to its high prevalenceMortality and the increasing number of hospital admissions for this condition. A coordinated healthcare
network involving general practitioners and cardiologists was set up in the east of Paris in an
effort to improve the management and outcomes of patients with severe heart failure.
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Aims.— To reinforce patient education, improve compliance with medications and identify
symptoms requiring treatment modiﬁcation.
Methods.— In this ‘before and after’ study, the control group comprised patients hospitalized
for severe heart failure who received conventional management in the year preceding the
network set-up. The comparative group consisted of patients hospitalized for severe heart
failure who underwent network-led care.
Results.— No signiﬁcant differences were found between rates of ﬁrst rehospitalization and
all-cause mortality at 1 year between control and network groups, or between rates of ﬁrst
hospitalization due to cardiac causes, time to the ﬁrst event, duration of hospitalization, rates
of cardiac death or time to death.
Conclusions.— In this non-randomized study, we found no beneﬁt from management according
to the RESICARD healthcare network in terms of mortality or hospitalization in patients with
severe chronic heart failure.
© 2009 Published by Elsevier Masson SAS.
MOTS CLÉS
Insufﬁsance
cardiaque ;
Mortalité
Résumé
Contexte.— L’insufﬁsance cardiaque (IC) représente un problème de santé publique majeur, lié
à sa forte prévalence, et à l’augmentation croissante des hospitalisations. Une coordination de
médecins généralistes et de cardiologues de ville et hospitaliers de l’est de Paris s’est constituée
dans le cadre d’un réseau ville—hôpital aﬁn de maintenir à domicile les patients insufﬁsants
cardiaques graves.
Objectifs.— Renforcer l’éducation du patient, s’assurer de l’observance du traitement et iden-
tiﬁer précocement les symptômes justiﬁant une modiﬁcation thérapeutique.
Méthodes.— La méthodologie utilisée était comparative, non randomisée. Les patients hospi-
talisés pour IC sévère dans les hôpitaux participants dans l’année précédant l’installation du
réseau et répondant aux critères d’inclusion ont constitué le groupe témoin ayant bénéﬁcié
d’un traitement conventionnel. Les patients hospitalisés pour IC sévère dans les hôpitaux par-
ticipants dans l’année suivant l’installation du réseau et répondant aux critères d’inclusion ont
constitué le groupe réseau ayant bénéﬁcié d’une prise en charge spéciﬁque.
Résultats.— Aucune différence signiﬁcative n’a été retrouvée concernant les taux de première
réhospitalisation et de mortalité à un an toutes causes confondues entre les groupes témoin
et réseau. De même, aucune différence signiﬁcative n’a été retrouvée concernant le taux
de première réhospitalisation pour cause cardiaque, le délai moyen de survenue par rapport
à l’inclusion et la durée moyenne d’hospitalisation. Aucune différence signiﬁcative n’a été
observée entre les deux groupes concernant les décès de cause cardiaque et leurs délais de
survenue par rapport à l’inclusion.
Conclusion.— Cette étude prospective non randomisée n’a montré aucun bénéﬁce à la prise en
charge par le réseau de soins RESICARD, en termes de réduction des hospitalisations et de la
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bbreviations
CE Angiotensin-converting enzyme
OACH Coordinating study evaluating outcomes of advising
and counseling in heart failure
P General practitioner
VEF Left ventricular ejection fraction
YHA New York Health Association
R Odds ratio
R Risk ratio
MV Outpatient medical coordinationackground
eart failure and its management present a major public
ealth concern. The magnitude of this problem is reﬂected
cross a wide range of evidence. Heart failure affects more
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han 4% of the adult population and more than 20% of those
ged 65 years and over—who represent a rapidly growing
omponent of the general population [1]. One in three adults
ver 55 will develop heart failure during their lifetime; the
-year survival rate is 35%, depending on the diagnosis [2].
his condition is the most common cause of hospitaliza-
ion in patients over 65 years [3]. More than one-quarter
f patients die within 1 year of diagnosis [4] and one-third
re readmitted within 6months of discharge [5]. Hospitaliza-
ion accounts for two-third of costs related to heart failure
6].
Despite recent progress in our understanding of the
athogenesis of heart failure and the therapies available
or its treatment [7], the prognosis for patients remains
oor and their quality of life is profoundly affected [8].
anagement strategies aimed at improving this situation
herefore appear necessary. Multidisciplinary management
or patients with heart failure after their discharge from
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hospital has been tested with success in Anglo-Saxon coun-
tries and in Sweden [9], reducing effectively both the
number of readmissions and, to a lesser extent, heart
failure-related mortality. In addition, recent European rec-
ommendations on the management of chronic heart failure
[7] recommend the creation of professional healthcare
groups to reduce both heart failure-related symptoms and
hospital admissions (class IA) and to improve survival rates
(class IB).
Since observations and potential solutions described in
the international literature were considered to be applica-
ble to France, a group of hospital- and community-based
cardiologists decided to create a healthcare network for
the management of patients with severe heart failure in
the Île-de-France area. These primary care physicians (GP
and cardiologists) and health service and private hospital
cardiologists collaborated to build a healthcare network,
RESICARD, covering the ‘‘bassin de Vie No. 1’’ (i.e., the
11th, 12th, 19th and 20th districts located on the east side of
Paris).
The primary aim of this network was to improve the
quality of life of patients with heart failure by reducing
midterm mortality and number of hospital readmissions.
In practical terms, the aims of RESICARD were to encour-
age closer cooperation between hospital and community
care environments, improve coordination between GP and
cardiologists and provide educational programmes tar-
geting both patients and their families. This approach
complied with the principles of Good Medical Practice
and ongoing efforts to improve the healthcare/expenditure
ratio, particularly by reducing hospitalization-related
costs.
Methods
Population
Patients were recruited from three Paris state university
hospitals (Saint-Antoine, Beaujon and Tenon) and one pri-
vate hospital (La-Roseraie). Patients were recruited at the
end of their hospitalization for acute cardiac decompensa-
tion. Inclusion criteria were as follows:
• age greater than 18 years;
• presence of criteria for severe heart failure as deﬁned
by the European Society of Cardiology [10] in patients
hospitalized in a cardiology intensive care unit;
• willingness to be monitored as stipulated in the protocol
and to be followed-up by a GP and a cardiologist on an
outpatient basis.
The exclusion criteria were as follows:
• recent transmural infarction (< 1month) resulting in con-
gestive heart failure;
• no history of congestive heart failure;
• valvular heart disease; reversible myocardial ischaemia
(planned revascularization over the short term) or
obstructive cardiomyopathy whose aetiological treatment
corrected the heart failure;
• serious renal or hepatic disease;
• NYHA functional class I or II at admission;
• any life-threatening or functionally incapacitating disease
such as cancer or chronic pulmonary disease;re 31
patients on a waiting list for a heart transplant;
multisite pacemaker;
long-term mechanical circulatory assistance;
scheduled discharge to a long-stay convalescent home;
personal or psychological criteria such as the patient’s
refusal to participate, lifestyle incompatible with regu-
lar monitoring, inability to understand and answer the
questionnaire;
participation in another protocol.
atient recruitment
n this ‘before and after’ study, patients were recruited at
articipating hospitals in two consecutive stages:
January 2001 to February 2002: inclusion of hospitalized
patients in the year preceding creation of the healthcare
network. This ‘control’ group was to receive conventional
care;
February 2002 to July 2003: inclusion of hospitalized
patients in the year following creation of the healthcare
network. This ‘network’ group was to receive network-led
care (therapeutic intervention group).
Patients meeting the inclusion criteria were informed
bout the working hypothesis, and two groups of patients,
reated according to the principles of Good Medical Practice,
ere considered. After discussion with themethodology spe-
ialists, it became obvious that randomization of patients
ould be difﬁcult [11] because of the risk of a protocol bias
rising during the appointment with the patient’s physician.
e therefore decided to apply a comparative methodology,
sing a ‘before and after’ approach in terms of creation of
he network.
unction of the healthcare network
his network was created as stipulated in legislation-
overning networks with an administrative council, a
teering committee and a scientiﬁc committee. It was
nanced by the Fond d’aide à la qualité des soins de
ille (Community Care Quality Fund or FAQSV), the Union
égionale des médecins libéraux d’Île-de-France (URML Île-
e-France Private Doctors Regional Union) and, to a very
imited extent, by the pharmaceutical industry but only for
ontinuous medical training meetings, brochures and infor-
ation videos provided to patients.
The monitoring scheduled, and in part carried out by the
etwork, involved 150GP and 25 community cardiologists for
ach region (East Paris), all of whom signed an agreement.
atients hospitalized for severe heart failure (stage III—IV) in
ne of the institutions taking part in the study were offered
peciﬁc care after their discharge. This consisted initially
f:
multidisciplinary management:
◦ an educational campaign for patients and their fami-
lies, which started at the hospital (patients were shown
a ﬁlm and given printed documents) and was to be con-
tinued at the doctor’s ofﬁce, with more information
to be handed to the patient and stored in his or her
personal treatment diary,
◦ personalized advice on diet,
◦ a meeting with a social worker;
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medical care:
◦ medications prescribed were left to the discretion
of the doctor, who was guided by current prescrip-
tion guidelines and Good Medical Practice (national
and international recommendations, consensus,
etc.),
◦ immediately upon their discharge, patients were
enrolled in the ‘network arm’ of the study (therapeutic-
intervention group), illustrated in Fig. 1 and were
given more regular and prearranged appointments with
their GP and cardiologist than they would have nor-
mally (control group, standard treatment). Patients
were asked to attend a ﬁrst appointment with the
GP within 72 hours of discharge from hospital. The
protocol stipulated that they visit their GP every
2weeks until the third month and once or twice each
month thereafter depending on their clinical condition.
Patients were requested to visit their cardiologist in
the ﬁrst week after discharge from hospital, followed
by a monthly appointment for 3months, then every
3months, again depending on their clinical condition.
Special care was made for each of these appointments
at which patients were advised on how best to manage
their disease. When necessary, additional appointments
were arranged for treatment adjustment, managing
complications, physiotherapy and advice on nursing
care;
availability of SMV. The role of the SMV was to coor-
dinate the network globally and to manage patients
individually. The SMV could be contacted by patients or
physicians for information and feedback. The SMV was
also responsible for contacting the patients regularly by
phone. The SMV consisted of an assistant doctor who
had received training in education measures for patients
with heart failure and whose role was to work closely
with a nurse to ensure that the patient’s educational
goals were met. Together, they provided patients with
educational information support and dietary advice, and
recorded patients’ weights, heart rates and blood pres-
sures on a weekly basis. In the event of deterioration in a
patient’s clinical condition (‘alarm signals’) or an emer-
gency, they informed the GP and/or cardiologist. They
answered the patient’s questions and assessed their level
of participation in the network and satisfaction with the
care provided. The team also included a social worker
and dietician. The aims of the SMV were to collect data
about the patients in the network, optimize coordina-
tion between GP and cardiologists for patient-education
purposes, guide patients with social problems and run
a medical telephone helpline open 24/7, through which
patients could remain in permanent contact with their
network doctor. All of the care received by patients was
recorded in their treatment diary, which they kept and
handed over to the healthcare provider at the different
appointments.
ollow-up and assessment criteriahe control group consisted of patients who were willing to
ake part in the study, with assessment being an integral
art of conventional treatment, in line with Good Medi-
al Practice. Clinical and sociodemographic information was
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ecorded at the time of inclusion (hospital discharge), then
t regular intervals via phone calls with the patients and/or
heir physician. Each time the patient was readmitted, fur-
her information was recorded. The patients were not given
ny planned appointments or speciﬁc examinations as part
f the assessment. They received care according to usual and
roven Good Medical Practice and their treatment was opti-
ized at the discretion of their physician and was recorded.
onversely, they were not given any speciﬁc educational
aterials.
Patients in both groups provided their informed consent
nd follow-up lasted for 12months.
ssessment criteria
he primary endpoints (primary assessment criteria) were:
onset of major cardiac events, deﬁned as readmission or
death from cardiovascular causes during follow-up;
interval between inclusion and onset of a major cardiac
event.
The secondary endpoints (evaluation criteria) were all-
ause death, total number of hospital readmissions, number
f readmissions for heart failure and duration of hospitaliza-
ion (days in hospital avoided).
ollow-up
atients were evaluated on the basis of a data grid, making
t possible to monitor changes in the objectives mentioned
bove. The evaluation was carried out at 6months and at
2months. The evaluation grid listed the patient’s condition
t the time of the evaluation, the care required since the
ast evaluation and a quality-of-life score.
tatistical analysis
he statistical analysis included:
comparisons of baseline data and of major events using
2 tests. All percentages were compared with non-
parametric exact tests;
comparisons of changes in clinical parameters: survival
curves were created and analysed using the Kaplan-Meier
method and a log-rank test;
evaluation of the effects on the primary endpoints of
individual management types (network, non-network) and
various demographic and clinical variables, using Cox
semiparametric proportional hazard models.
esults
aseline characteristics of study population
total of 454 patients were enrolled at the end of the
ecruitment period, 25 of whom were excluded immedi-
tely: 15 at the beginning of the study and 10 who were
ither excluded from the protocol or lost to follow-up. The
nal study population therefore comprised 429 patients: 211
ere enrolled during the control phase (control group, con-
entional care) and 218 during the network phase (network
roup, therapeutic intervention).
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Sociodemographic characteristics and
heart-failure proﬁles
The sociodemographic characteristics and heart-failure pro-
ﬁles of the patients are shown in Table 1. There was no
signiﬁcant difference in themean age of control and network
groups (73.8± 13.4 versus 72.1± 14.3 years, respectively).
A higher proportion of patients in both groups were men
(56.9% versus 59.6%, respectively). No signiﬁcant difference
in inclusion site was observed between the two groups, with
most patients being enrolled at the Tenon and Saint-Antoine
university state hospitals. Most patients in both groups were
independent of each other and had no history of heart failure
in the year preceding their inclusion (control group 79.7%
versus network group 84.8%). Conversely, patients in the
network group showed a signiﬁcant improvement in their
functional status after discharge versus preadmission com-
pared to the patients in the control group (p < 0.001), as
evidenced by the three-class drop in NYHA functional class
observed in 20.7% of cases versus 1.9% of controls and the
two-class drop in 44.6% of cases versus 38.8% of controls.
Indeed, 9.8% of patients in the network group versus 24.2%
in the control group were in NYHA class III at discharge.
Ischaemic heart disease was the most common cause of
heart failure in both groups but with a signiﬁcantly greater
t
p
w
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dccurrence difference in the network group (53.2% versus
2.7%, p = 0.028). Conversely, dilated cardiomyopathy was
ore common in the control group than in the network group
30.3% versus 21.6%, p = 0.038). At least one triggering fac-
or for the initial episode of heart failure was found in both
roups (68.6% versus 70.6%). Dysrrhythmia was the most
ommon triggering factor in the control group whereas poor
reatment compliance followed by dysrrhythmia were the
ost common factors in the network group. Poor compliance
ith treatment at admission was more frequently observed
n the network versus the control group (Table 1).
linical, paraclinical and therapeutic
haracteristics
o signiﬁcant differences were observed between groups for
he results of the clinical examinations performed on admis-
ion and at discharge. An overall improvement in the clinical
ondition of patients was observed during the initial period
n hospital, with alleviation of the physical signs of conges-
ive heart failure in both groups (Table 2). Conversely, the
rescribed discharge medications varied between groups,
ith beta-blockers (64.7% versus 48.8%, p = 0.0009), ACE
nhibitors (80.7 versus 67.8%, p = 0.002), potassium-sparing
iuretics (36.2 versus 19.9%, p = 0.0002) and statins (34.9
34 P. Assyag et al.
Table 1 Sociodemographic and medical characteristics of patients at inclusion.
Control group n = 211 Network group n = 218 p
Men (%) 56.9 59.6 NS
Age in years (mean± S.D.) 73.8± 13.4 72.1± 14.3 NS
Inclusion site (%)
Beaujon Hospital 22.9 18.6 NS
La-Roseraie Hospital 9.2 8.4 NS
Saint-Antoine Hospital 33.5 35.9 NS
Tenon Hospital 34.4 37.1 NS
Extent of dependency (%)
Independent 84.2 88.8 NS
‘Lives alone’ 46.6 41.6 NS
Heart failure episode in previous year 20.3 15.2 NS
Number of heart failure episodes in previous year (%)
0 70.5 76 NS
1 20.3 15.2 NS
2 6.3 6 NS
3 1.5 1.4 NS
4 1.5 1.4 NS
NYHA class at admission (%)
III 41 47 NS
IV 58.1 51.2 NS
NYHA class at discharge (%)
I 2.9 39.7 0.0001
II 71.5 50 0.0001
III 24.2 9.8 0.0001
IV 1.5 0.5 0.0001
Change in NYHA (%): NYHA at discharge—NYHA at admission
Drop 3 classes 1.9 20.7 0.0001
Drop 2 classes 38.8 44.6 0.0001
Drop 1 class 49.5 27.2 0.0001
No drop in class 9.7 7.5 0.0001
Aetiology of heart failure
Ischaemic heart disease 42.7 53.2 0.028
Hypertensive cardiopathy 13.7 17 NS
Valvular disease 30.8 33.5 NS
Dilated cardiomyopathy 30.3 21.6 0.038
Others 7.6 5 NS
Triggering episode
Dysrrhythmias 23.3 26.1 NS
Poor treatment compliance 17.6 26.6 0.025
Infection 13.8 12.4 NS
Hypertensive episode 9 5.5 NS
Myocardial infarction 2.4 4.6 NS
Angina 4.7 1.4 0.04
Iatrogenic 2.9 3.2 NS
Introduction of beta-blockers 0.9 0.5 NS
At least one triggering factor 68.6 70.6 NS
No triggering factor 31.4 29.4 NS
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CNYHA: New York Heart Association; S.D.: standard deviation; NS:
ersus 24.5%, p = 0.02) prescribed more frequently in the
etwork group.No signiﬁcant difference was observed between groups in
erms of the conventional laboratory test proﬁle obtained
n admission and at discharge. In both groups, the
ean concentration of serum creatinine was approximately
23mol/L at discharge. Similarly, no signiﬁcant differences
a
b
g
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signiﬁcant.
ere found in the electrocardiographic anomalies observed.
hest X-rays taken at admission showed cardiomegaly, with
cardiothoracic index greater than 0.6 in most patients in
oth groups, more frequent alveolar oedema in the control
roup (74.7% versus 57.7%; p = 0.003) and, by contrast, more
requent pleural effusion in the network group (37.4 ver-
us 27.1%; p = 0.026). Approximately one-half of the patients
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Table 2 Clinical and paraclinical data for patients in the two groups at admission and discharge.
Control group n = 211 Network group n = 218 p
Weight on admission, kg (mean± S.D.) 73.5± 18.6 76± 19.7 NS
Weight on discharge, kg (mean± S.D.) 72.2± 17.6 71.5± 18.2 NS
Lower limb oedema at admission (%) 58.6 52.8 NS
Lower limb oedema at discharge (%) 10.8 6.9 NS
STJ at admission (%) 41.5 46.1 NS
STJ at discharge (%) 7.4 7 NS
HRJ at admission (%) 45.8 50.2 NS
HRJ at discharge (%) 10 7.9 NS
Rates at admission (%) 86.5 80.7 NS
Treatments on admission and at discharge (%)
Diuretics at admission 54 57.8 NS
Diuretics at discharge 82 88.1 NS
Potassium-sparing diuretics at admission 11.4 13.3 NS
Potassium-sparing diuretics at discharge 19.9 36.2 0.0002
ACE at admission 42.6 50.5 NS
ACE at discharge 67.8 80.7 0.002
ARA II at admission 8.1 7.3 NS
ARA II at discharge 5.2 2.3 NS
Beta-blockers at admission 26.1 35.8 0.029
Beta-blockers at discharge 48.8 64.7 0.0009
Diuretic + ACE or + ARA II 61.1 76.1 0.0008
Statins at admission 0.9 2.7 NS
Statins at discharge 24.6 34.9 0.02
Laboratory tests (mean± S.D.)
Sodium at admission (mmol/L) 137.4± 4.6 137.3± 4.4 NS
Sodium at discharge (mmol/L) 136.4± 4 136.2± 3.9 NS
Haemoglobin at admission (g/dL) 13.2± 2 13± 2 NS
Haemoglobin at discharge (g/dL) 12.7± 2.2 12.8± 2 NS
Creatinine at admission (mol/L) 116.8± 52.8 113.4± 47.3 NS
Creatinine at discharge (mol/L) 123.1± 58.1 123.2± 49.6 NS
Electrocardiogram admission (%)
Sinus rhythm 64.1 61.4 NS
Left bundle branch block 31 27.8 NS
Left ventricular hypertrophy 24.2 17.9 NS
ST-segment abnormalities 44.9 52.6 NS
Cardiac ultrasound at admission (LVEF) (%)
< 20% 10.3 10.4 NS
20—40% 48 50.5 NS
40—50% 16.7 18.9 NS
> 50% 25 20.3 NS
Chest X-ray at admission (%)
Cardiomegaly 81.4 78 NS
Alveolar oedema 74.7 57.7 0.003
Interstitial oedema 90.1 88.3 NS
Pleural effusion 27.1 37.4 0.026
sin II
D.: s
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wACE: angiotensin-converting enzyme inhibitors; ARA II: angioten
veins; HRJ: hepatic reﬂux in jugular veins; n/a: not applicable; S.
enrolled in the study had a LVEF between 20% and 40% on
the echocardiogram. LVEF was preserved (> 50%) in one-ﬁfth
to one-quarter of patients, with no signiﬁcant difference
observed between the two groups.Primary endpoints
No signiﬁcant differences were observed between the con-
trol or network groups in the number of deaths from
m
r
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treceptor antagonist; STJ: spontaneous turgescence of jugular
tandard deviation; NS: non signiﬁcant.
ardiovascular causes (9.9% versus 8.6%, respectively) or
n the mean time of onset after inclusion (158.8± 92.8
ersus 167.3± 102.4 days, respectively) (Table 3). This
as also the case for the numbers of ﬁrst read-
issions for cardiovascular causes (27.7 versus 31.1%,
espectively) and the mean time for readmission after inclu-
ion (96.9± 79.5 versus 107.5± 94.7 days, respectively)
Table 4). Finally, the mean duration of hospitaliza-
ion for cardiovascular causes was comparable in both
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Table 3 One-year mortality and time to death in network and control groups.
Control group n = 211 Network group n = 218 p
All-cause death (%) 21.6 18.6 NS
Death from cardiac cause (%) 9.9 8.6 NS
Time to onset after inclusion (days)* 158.6± 92.8 167.3± 102.4 NS
Death from heart failure (%) 6.3 6.5 NS
Time to onset after inclusion (days)* 164.1± 86.9 157.8± 108.6 NS
NS: not signiﬁcant; S.D.: standard deviation.
* mean± S.D.
Table 4 First readmission and time to onset in control and network groups.
Control group n = 211 Network group n = 218 p
First readmission for all causes (%) 50.7 54.6 NS
First readmission for cardiac cause (%) 27.7 31.1 NS
Time to onset after inclusion (days)* 96.9± 79.5 107.5± 94.7 NS
Duration of hospitalization (days)* 12.7± 11.7 13.3± 13.5 NS
First readmission for cardiac failure (%) 22.2 26.5 NS
Time to onset after inclusion (days)* 92.2± 74.1 116.1± 97 NS
Duration of hospitalization (days)* 13.3± 12.3 14.9± 14 NS
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* mean± S.D.
roups (12.7± 11.7 versus 13.3± 13.4 days, respectively)
Table 4).
econdary endpoints
o signiﬁcant difference was observed between groups in
he overall 1-year mortality rate, irrespective of cause (con-
rol group 21.6% versus network group 18.6%) (Table 3).
imilarly, all-cause readmission rates were also compara-
le (Table 4). In addition, no signiﬁcant differences were
bserved in the number of deaths from heart failure and
heir time of onset calculated from the date of inclusion
Table 3). The rate of ﬁrst readmissions for heart failure,
he interval between discharge and readmission, and the
uration of hospitalization were comparable (Table 4).
ajor cardiac event-free survival (death from
ardiac cause or readmission for cardiac reasons)
he network approach did not impact on the interval
etween inclusion and the onset of a major cardiac event,
r on the probability of such an event occurring by itself
Fig. 2).Survival curves plotted for clinical variables known to be
ndicators of a poor prognosis (discharge NYHA class, exis-
ence of ischaemic heart disease and number of episodes
f heart failure in the preceding year) conﬁrmed their
redictive value for major cardiac events (Fig. 3). Dual
(
C
d
m
igure 3. Kaplan-Meier curves showing event-free survival in controls
eart disease; C. History of heart failure episodes; D. Intensity of RESIC
unction of number of GP and cardiologist appointments.igure 2. Kaplan-Meier curve showing event-free survival in con-
rol and network groups.
tratiﬁcation of the survival curves by inclusion group, and
hese indicators taken individually, showed that the net-
ork did not exert a protective effect against the onset of a
ajor cardiac event as a function of these three parameters
Fig. 3A—C).
The survival curves were stratiﬁed using the two RESI-
ARD monitoring intensity indicators with the aim of
istinguishing, within the network group, the patients
onitored as stipulated in the protocol and poorly or
and network groups. A. NYHA class; B. Existence or not of ischemic
ARD monitoring: as a function of frequency of SMV calls. E. As a
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nmonitored patients, thus reﬁning the ‘network effect’
nalysis. The ﬁrst indicator was SMV monitoring, for which
hree groups of patients were studied: controls, those
nsufﬁciently monitored by the SMV (< 1.5 calls per month)
nd those correctly monitored by the SMV (> 1.5 calls per
onth) (Fig. 3D). The second RESICARD monitoring indi-
ator compared patients who never visited their GP or
ardiologist (n = 40), those who rarely or only occasionally
ttended appointments (GP < 0.4 times per month, cardi-
logist > 0.2 times per month) and those who saw their
ealthcare provider regularly (GP > 0.4 times per month,
ardiologist > 0.2 times per month) (Fig. 3E). The two curves
btained show that intense monitoring by the SMV and more
requent medical appointments (GP and cardiologist) exert
marginally protective effect on the onset of major cardiac
vents, but this trend was not statistically signiﬁcant.
actors associated with onset of major cardiac
vents and cardiac mortality at 1 year
n multivariable analysis using Cox’s semiparametric pro-
ortional modelling, after adjustment for cardiovascular
isk factors (age, sex, hypertension and smoking), pres-
nce of ischaemic heart disease, NYHA functional class
t discharge, LVEF and history of heart failure, the only
ndependent parameters signiﬁcantly associated with the
nset of major cardiac events were history of heart fail-
re (p = 0.05), other heart disease (p = 0.0004) and NYHA
lass at discharge (p = 0.0033). Global management via the
etwork (p = 0.23), intensity of monitoring received via the
MV (p = 0.9) and frequency of appointments with the GP
r cardiologist (p = 0.3) had an impact on the primary end-
oints, time to onset between inclusion and major cardiac
vents.
In a second multivariable analysis adjusting for age,
ex, NYHA class at discharge, history of cardiac disease,
ospital at which the patient was enrolled, type of heart dis-
ase and treatments at discharge (diuretics, ACE inhibitors,
ngiotensin II receptor antagonists, beta-blockers), the only
ndependent parameters associated with cardiac mortality
t 1 year were history of at least one episode of heart fail-
re in the preceding year (OR 2.9, 95% conﬁdence interval
95% CI] 2.2—15.7; p = 0.02) and NYHA class II or IV at dis-
harge (OR 2.9, 95% CI 1.1—7.3; p = 0.02). Management by
he network (OR 1.02, 95% CI 0.4—2.3; p = 0.9), intensity
f SMV follow-up and frequency of appointments were not
ndependent predictors for cardiac mortality (OR 0.7, 95%
I 0.2—3.1; p = 0.7 and 0.9, 0.3—2.8; p = 0.8, respectively).
iscussion
his prospective, non-randomized study examined a collabo-
ative network of different healthcare professionals (health
ystem and private practice) who followed a multidisci-
linary outpatient approach to the management of acute
eart failure. The results do not concur with the literature,
ince no beneﬁt was found for patients managed by the
ESICARD network in terms of readmissions or mortality.
Several studies have demonstrated the beneﬁts of multi-
isciplinary care for patients with chronic heart failure after
ischarge [12—20]. While most report favourable results, not
ll have shown a positive effect [21—24]. For example, the
t
a
o
n
gP. Assyag et al.
andomized multicentre COACH study [24], which included
ne of the largest series of patients described since the
dvent of extrahospital heart failure management networks
n = 1024), did not show that this management approach had
signiﬁcant effect on the combined primary endpoint, read-
issions and mortality subsequent to heart failure when
ompared to the control group receiving conventional care.
hus, in view of the disparities in the results published,
t appears necessary to analyse the different factors that
ould explain the lack of signiﬁcant differences in our net-
ork experience with regard the incidence of events in the
ontrol and network populations.
etwork strategy and implementation
he ﬁndings from studies reporting positive results for mul-
idisciplinary network management of discharged patients
ary depending on the event examined (mortality or read-
ission) and the type of programme applied. A recent
eta-analysis [9] explored the results of 29 randomized tri-
ls, with the aim of stratifying the beneﬁts obtained as a
unction of the strategy adopted, and showed that follow-
p by a multidisciplinary specialist team in a medical setting
doctor’s ofﬁce or clinic) or via home visits led to a signiﬁ-
ant reduction in mortality (RR 0.75, 95% CI 0.59—0.96) and
eadmissions for heart failure (RR 0.74, 95% CI 0.63—0.87)
r for all causes combined (RR 0.81, 95% CI 0.71—0.92).
ncouraging self-care and education through a telephone
dvisory system or nurse-led information programme dur-
ng home visits led to a signiﬁcant reduction in readmissions
or heart failure (RR 0.66, 95% CI 0.52—0.83) and all read-
issions (RR 0.73, 95% CI 0.57—0.93) but did not have any
mpact on mortality (RR 1.14, 95% CI 0.67—1.94). Finally,
sing telephone calls to encourage patients to see their doc-
or if their condition worsened led to a signiﬁcant decrease
n the number of readmissions for heart failure (RR 0.75,
5% CI 0.57—0.99) but did not have a signiﬁcant effect on
ortality (RR 0.91, 95% CI 0.67—1.29) or all-cause read-
issions (RR 0.98, 95% CI 0.80—1.20). In spite of these
uances, the meta-analysis remains on the whole positive
nd in favour of a multidisciplinary approach, irrespec-
ive of the strategy employed. Nonetheless, these results
uggest that physician expertise, a carefully structured mul-
idisciplinary teamwork and long and detailed preparation
efore implementation are required for this kind of out-
atient management programme to be of optimal beneﬁt
o patients. Training qualiﬁed staff and developing links
mongst the various healthcare professionals involved is a
rimary objective and one that is indeed difﬁcult to achieve
25].
The strategy adopted in RESICARD aimed to be ‘opti-
al’ in that after discharge, patients were given a series
f appointments with their GP and cardiologist at regular
nd tailored intervals over a 3-month period and were then
onitored by the multidisciplinary SMV team. In our anal-
sis, stratiﬁcation of survival curves as a function of the
wo monitoring intensity indicators (Fig. 3D and E) showed
hat intense monitoring by SMV and more frequent medical
ppointments (GP and cardiologist) had a protective effect
n the onset of major cardiac events, although this trend was
ot statistically signiﬁcant. Should precedence have been
iven to home visits rather than to phone calls, as was the
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case in the studies reporting optimal results? This assertion
remains a matter of debate.
Questions that could arise regarding McAlister et al.’s
meta-analysis [9] concern the fact that although the indi-
rect comparisons of the studies analysed were adjusted,
evaluation of the relative beneﬁts of the different parts
of each type of management plan could be biased by the
absence of direct comparison. For example, one study [26]
reported that a daily phone call to patients supervised by
a nurse was more effective and less costly than home vis-
its by nurses who lacked specialization in heart failure.
Moreover, the recent COACH study [24] tested two lev-
els of monitoring intensity (moderate: appointment with
the cardiologist + contact with a nurse; intensive: appoint-
ment with a cardiologist + contact with a nurse + home
visits +multidisciplinary team comprising dietician, physio-
therapist and social worker) versus a control group receiving
conventional care (cardiologist appointment) and found no
difference in the onset of adverse events as a function of
the strategy applied (control group 42%; moderate mon-
itoring group 41%, hazard ratio 0.96, p = 0.73; intensive
monitoring group 38%, hazard ratio 0.93, p = 0.52). Thus,
direct comparison with other types of management plans
(or monitoring intensity) appears to be next step requiring
investigation.
Time dedicated to learning within the network
Three elements appear fundamental to the success of
a multidisciplinary management program. The ﬁrst of
these—availability of nursing staff who have received spe-
cialized training in the management of an elderly population
presenting with several comorbid conditions and who are
sometimes difﬁcult to deal with owing to cognitive impair-
ment, instability and/or psychological difﬁculties— is the
cornerstone of all management programs. The second ele-
ment is the time and effort invested by staff in educating
patients and their families about the disease, what trig-
gers it and the importance of complying with treatment
and diet plans, making it necessary to preselect patients
considered most likely to beneﬁt from a network-care sys-
tem. The third and last element is the willingness of patients
to consult healthcare professionals trained in heart failure
care. The meta-analysis by McAlister et al. [9] found that
27 of 29 studies were conducted in high-risk cardiac failure
patients (recently discharged from hospital), and that all
the programmes were run by trained teams from specialist
teaching hospitals and centres. The authors of this meta-
analysis also highlighted the fact that the beneﬁts observed
in their study could not with certainty apply to low-risk
patient groups, especially if the care programmes concerned
were run by teams that had not received the requisite train-
ing. However, the RESICARD network differs in several ways:
it was designed for all patients hospitalized for acute heart
failure in an intensive care unit but without preselection on
the basis of potential compliance; the specialist staff was
located in the community (and not in hospitals) and the
patient monitoring programme meant that doctors in the
outpatient sector were involved heavily. Moreover, as part
of the RESICARD network, healthcare providers were obliged
to take on new roles and learn new tasks such as patient
education, and this was a lengthy process. This bias is not
4
r
p
p
tre 39
uantiﬁable but could explain, at least in part, the neutral
etwork effect observed.
ptimal medical treatment and monitoring
arge studies evaluating current medical practices in Europe
or heart failure continue to show that evidence-based
edicine is still not sufﬁciently available [27]. In recent
eta-analyses [9,28—30] evaluating the beneﬁts of net-
ork management after discharge, few studies report the
requency of ACE inhibitor or beta-blocker prescription,
aking it impossible for the authors of meta-analyses to
onclude as to the speciﬁc and additional beneﬁts of such
rogrammes, since the beneﬁts observed could simply be
ttributed to optimal guideline-based practices or patient
ompliance with treatment. In RESICARD, a high propor-
ion of patients in both control and network groups were
rescribed beta-blockers (48.8% versus 64.7%, respectively)
nd ACE inhibitors (67.8% versus 80.7%) when they were dis-
harged home, with signiﬁcant differences in favour of the
etwork group (Table 2). We cannot therefore rule out the
ossibility that the negative result obtained in this study
ould be related to the fact that patients in both groups
ere receiving optimal treatment after hospital discharge.
or obvious reasons, it is difﬁcult to obtain and measure a
etwork-speciﬁc effect in a group receiving optimal medical
reatment.
This hypothesis is supported by the relatively low inci-
ence of events measured in the control group in our study,
hich was comparable to that reported in the COACH study
24], indicating that patients were managed in a satisfactory
anner before RESICARD was set up.
In the initial studies [9], patients in the control group
id not receive any specialist follow-up, which could
xplain the higher incidence of events. In our study as
ell as in the COACH study [24], patients in the con-
rol group were conventionally monitored by a cardiologist,
hich might improve the likelihood of receiving optimal
anagement.
eart failure due to systolic dysfunction
ersus preserved LVEF
n our study, about 60% of patients in both groups had
n LVEF of less than 40% (p =NS). LVEF was preserved
LVEF > 50%) in about one-quarter of cases in both groups and
etween 40% and 50% in the remainder. Similarly, patients
ith both altered and preserved LVEF were enrolled in the
OACH study [24], with a mean LVEF of 34%. Very few
eta-analyses reporting the positive effects of multidis-
iplinary management programmes mention whether the
tudies analysed included both heart failure patients with
ystolic dysfunction and those with preserved LVEF [28,29].
n the meta-analysis by Holland et al. [28], only 15 of the
0 studies included reported the baseline LVEF, with values
arying from 22% to 43%. Similarly, in the six-study meta-
nalysis by Phillips et al. [29], LVEF was between 27% and
1%, with a mean of 34%. In view of the lack of precision
egarding LVEF and given the prognosis for heart failure with
reserved LVEF, we cannot rule out the possibility that the
ositive results obtained in these studies could be related
o recruitment bias.
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tudy population: limitations associated with
on-randomization
n this unusual context, in which a medical practice rather
han a medication is tested, it appeared difﬁcult to pro-
ose randomization at discharge. We did consider patient
andomization (testing the protocol) but felt that we
ould encounter a protocol bias given that it would be
ifﬁcult for cardiologists to monitor patients in the conven-
ional and therapeutic-intervention groups. Randomization
f physicians also appeared difﬁcult. This led us to adopt a
before and after’ approach, particularly since the initial
eta-analysis [31] of the ﬁrst non-randomized multidis-
iplinary management studies, which also used the same
ethod as ours (ok?), had reported convincing results. Seven
on-randomized studies were analysed; the aims of the pro-
ramme were to improve compliance with recommended
ptimal treatments, reinforce patient education and opti-
ize monitoring. The follow-up period was in excess of
months. Five studies reported a signiﬁcant improvement in
he functional status of patients, their aerobic capacity and
uality of life. Six studies showed a 50—80% reduction in the
isk of readmission, leading the authors of the meta-analysis
o suggest a potential beneﬁcial effect of this type of man-
gement on readmission rates. However, non-randomization
s the primary limitation of prospective observational studies
n general and of the study we conducted in particular, since
t makes it impossible to exclude the presence of unknown
iases, making interpretation of the results speculative.
onclusions
arge-scale heart failure management programmes exist
n many countries. Recent recommendations encourage
he development of specialist outpatient management
rogrammes with the objective of improving symptoms,
educing hospitalizations and increasing survival rates. Our
on-randomized, prospective study did not show that inclu-
ion in the RESICARD healthcare network had a beneﬁcial
ffect on the number of hospitalizations or the mortality
ate in this patient group. However, it did suggest that
ntensive monitoring by an SMV (community medical coordi-
ation) and attending appropriate medical appointments did
ave a slightly protective (although not signiﬁcant) effect
gainst the onset of major cardiac events. Although the
esults were negative, this study allowed us to explore the
ifﬁculties related to setting up a heart failure management
etwork involving a variety of healthcare professionals and
n training qualiﬁed staff dedicated to this task. While the
iterature has shown that factors play a key role in the suc-
ess of these programmes, the elements truly responsible
or the favourable effects have yet to be identiﬁed. To solve
his problem, additional studies measuring monitoring and
anagement intensity, in particular, are required.eferences
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